KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Raw Materials (2016 - 2022)

TherapeuticsMD (TXMD) has disclosed Raw Materials for 11 consecutive years, with $1.9 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Raw Materials fell 44.19% year-over-year to $1.9 million, compared with a TTM value of $1.9 million through Sep 2022, down 44.19%, and an annual FY2021 reading of $3.0 million, down 18.84% over the prior year.
  • Raw Materials was $1.9 million for Q3 2022 at TherapeuticsMD, up from $434000.0 in the prior quarter.
  • Across five years, Raw Materials topped out at $5.7 million in Q4 2019 and bottomed at $19400.0 in Q4 2018.
  • Average Raw Materials over 5 years is $3.0 million, with a median of $3.6 million recorded in 2020.
  • The sharpest move saw Raw Materials surged 29290.45% in 2019, then crashed 90.43% in 2022.
  • Year by year, Raw Materials stood at $19400.0 in 2018, then soared by 29290.45% to $5.7 million in 2019, then plummeted by 34.27% to $3.7 million in 2020, then dropped by 18.84% to $3.0 million in 2021, then plummeted by 36.03% to $1.9 million in 2022.
  • Business Quant data shows Raw Materials for TXMD at $1.9 million in Q3 2022, $434000.0 in Q2 2022, and $4.4 million in Q1 2022.